Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 5:11:332.
doi: 10.3389/fnagi.2019.00332. eCollection 2019.

Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease

Affiliations

Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease

Xiaoyu Dong et al. Front Aging Neurosci. .

Abstract

Background: Biomarker screening is of major significance for the early diagnosis and prevention of Alzheimer's disease (AD). Routine peripheral blood parameters are easy to collect and detect, making them ideal potential biomarkers. Thus, we aimed to evaluate the parameters from routine blood as potential biomarkers for AD.

Methods: We enrolled 56 AD patients, 57 mild cognitive impairment (MCI) patients, and 59 healthy elderly controls. Receiver operating characteristic (ROC) curves were used to assess the diagnostic values of routine blood biomarkers in patients with cognitive impairment.

Results: There were significant differences in eight parameters between the groups. Logistic regression revealed that the neutrophil% (odds ratio (OR) 1.34, 95% confidence interval [CI] 1.03-1.75, p = 0.031) and neutrophil-to-lymphocyte ratio (NLR; OR 6.27, 95% CI 3.98-9.82, p = 0.003) differentiated AD patients and controls (areas under the curve [AUCs], 0.728 and 0.721) and that the NLR (OR 1.93, 95% CI 1.07-3.47, p = 0.028) and mean platelet volume (OR 1.67, 95% CI 1.04-2.70, p = 0.036) differentiated MCI patients and controls (AUCs, 0.60 and 0.638). There were no effective diagnostic biomarkers to distinguish AD from MCI.

Conclusion: Some routine blood biomarkers may correlate with cognitive impairment. Analysis of these biomarkers, such as the NLR, may be useful for the identification of patients with cognitive impairment.

Keywords: Alzheimer disease; aging; biomarkers; blood routine; mild cognitive impairment.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Boxplots for the eight parameters (A–H) with significant differences in concentrations between diagnostic groups. AD, Alzheimer’s disease; MCI, mild cognitive impairment; CTRs, controls; PDW, platelet distribution width; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
FIGURE 2
FIGURE 2
(A) AD patients and CTRs are differentiated by the NLR with a predictive power (AUC) of 0.721 (violet line) and by the neutrophil% with a predictive power (AUC) of 0.728 (red line). (B) MCI patients and CTRs are differentiated by the NLR with a predictive power (AUC) of 0.601 (green line) and by the MPV with a predictive power (AUC) of 0.690 (blue line).

Similar articles

Cited by

References

    1. Adeoye O., Walsh K., Woo J. G., Haverbusch M., Moomaw C. J., Broderick J. P., et al. (2014). Peripheral monocyte count is associated with case fatality after intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis. 23 e107–e111. 10.1016/j.jstrokecerebrovasdis.2013.09.006 - DOI - PMC - PubMed
    1. Akil E., Bulut A., Kaplan I., Ozdemir H. H., Arslan D., Aluclu M. U. (2015). The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol. Sci. 36 423–428. 10.1007/s10072-014-1976-1 - DOI - PubMed
    1. Arikanoglu A., Yucel Y., Acar A., Cevik M. U., Akil E., Varol S. (2013). The relationship of the mean platelet volume and C-reactive protein levels with mortality in ischemic stroke patients. Eur. Rev. Med. Pharmacol. Sci. 17 1774–1777. - PubMed
    1. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., et al. (2004). Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63 828–831. 10.1212/01.wnl.0000137040.64252.ed - DOI - PubMed
    1. Baird A. L., Westwood S., Lovestone S. (2015). Blood-based proteomic biomarkers of Alzheimer’s disease pathology. Front. Neurol. 6:236. 10.3389/fneur.2015.00236 - DOI - PMC - PubMed

LinkOut - more resources